Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
VAK-694 Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562745
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
VAK-694 also known as Anti-Binetrakin mAb is a humanized monoclonal antibody utilized in research settings focused on inhibiting interleukin signaling pathways. This biosimilar targets the interleukin-4 (IL-4) receptor playing a pivotal role in modulating immune responses often implicated in allergic conditions and certain cancers. The monoclonal antibody class of VAK-694 is IgG1 produced in XtenCHO expression systems and is utilized predominantly for its high specificity and affinity for IL-4 receptors. Its formulation in phosphate-buffered saline and storage requirements reinforce its stability and viability for experimental applications. The VAK-694 biosimilar is integral in studies exploring the combination with other monoclonal agents such as dectrekumab which targets IL-13 to disrupt pathways that contribute to inflammatory diseases and oncological conditions. These findings contribute to the ongoing efforts to design effective therapeutic strategies for diseases driven by cytokine dysregulation.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
